As a Medical Science Liaison, Eileen Rich fosters relationships with US healthcare providers to gather valuable insights to inform our clinical trial designs and research. Her background as an oncology nurse deepens her connection to her work, supporting #Arvinas' mission to improve the lives of patients with serious diseases by pioneering therapies created with our revolutionary PROTAC® protein degradation platform. Eileen collaborates cross-functionally with members of #TeamArvinas in support of our goal of launching potential new therapeutic options for patients. When she's not working, Eileen enjoys hiking, traveling, and spending time with her husband and friends. With a son in college and a daughter finishing high school, she loves exploring new destinations and cherishes family time. #MeetTeamArvinas #TPD #WorkAtArvinas #EmployeeExperience #CompanyCulture
Arvinas
Biotechnology Research
New Haven, Connecticut 22,130 followers
Leading the way in targeted protein degradation therapeutics
About us
Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC® Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC® targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including vepdegestrant, targeting estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-102, targeting LRRK2 for neurodegenerative disorders; and ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma. Based in the biotech hub of New Haven, CT, Arvinas is driven by an industry-leading team dedicated to improving the lives of people living with serious diseases. For more information, visit www.arvinas.com. Community Guidelines: http://bit.ly/ArvinasCG
- Website
-
www.arvinas.com
External link for Arvinas
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- New Haven, Connecticut
- Type
- Public Company
- Founded
- 2013
Locations
-
Primary
395 Winchester Ave.
5 Science Park
New Haven, Connecticut 06511, US
Employees at Arvinas
-
Steve Weiss
Senior Vice President, Chief Human Resources Officer
-
Petal B.
HR Director | Project Manager | Operations Leader | Strategic Initiatives | Everything DiSC Partner | MWBE: NYS, NYC, NY & NJ Port Authority
-
John Houston
-
Roy Haskell
Executive Director, Formulation R&D at Arvinas
Updates
-
Today we recognize #BreastCancerResearchDay and celebrate the tremendous progress that has been made in #breastcancer research. However, we also recognize that 1-in-8 women will still be diagnosed with breast cancer in their lifetimes and there is an urgent need for new advancements. That’s why we continue our commitment to investigating new treatment options for those living with breast cancer and our mission to improve the lives of patients. #Biotech #Innovation #Science
-
Our Chairperson, CEO and President John Houston recently sat down with Ian Taylor, Ph.D., President, Research and Development to record a vlog where they discussed Ian's inspiring career journey, the invaluable guidance he received from his mentors, and his secrets to staying motivated. Tune in below to discover the lessons he's learned and the wisdom he shares. #Motivation #ProfessionalGrowth
I recently had a fantastic conversation with the Arvinas President of R&D, Ian Taylor, and it's a must-watch in my opinion! Ian shares his incredible career journey, the impact of his mentors, how he’s stayed motivated, and the valuable lessons he's learned along the way. Thanks for chatting, Ian! https://lnkd.in/e4vWvCX5
-
Today’s #ScienceOfPROTAC focus is on the body’s primary mechanism for protein degradation - the ubiquitin-proteasome system. See how our PROTAC® technology aims to harness this system to destroy disease-causing proteins: https://bit.ly/3Sy8NKz #biotech #science
-
Our Chief Business Officer, Randy Teel, delves into the groundbreaking world of #targetedproteindegradation in a recent interview with Daniel Levine. He explores #TPDs evolution as a therapeutic strategy and the diverse therapeutic areas #Arvinas is pursuing. Tune in to the full interview to gain deeper insights into our innovative work. #TeamArvinas #Innovation #ProteinDegradation #Leadership
Randy Teel, chief business officer and interim chief financial officer of Arvinas, discusses protein degradation, its evolution as a therapeutic strategy, and the range of indications the company is pursuing. https://lnkd.in/gzsnvFtb
-
#NEWS: Today #Arvinas shared Q2 financial earnings and a business update. Read the release here: https://rb.gy/bpooti #investors #biotechnews
-
It was an honor to accept our award and recognize all of the honorees at this year's Healthcare & Life Sciences Awards. Thank you Greater New Haven Chamber of Commerce for awarding us Bioscience Company of the Year. Thank you BioCT for your endless support and thank you John Houston for representing #TeamArvinas!
Congratulations to the Greater New Haven Chamber of Commerce on executing another not-to-be-missed event, the ‘Heath Care & Life Sciences Awards’ at Canal Dock. We extend our congratulations to all the award winners, including Arvinas for Bioscience Company of the Year. BioCT board member John Houston accepted the award and was introduced by board member Carter Winstanley. We were also thrilled to see Mary Ann Melnick and BioLabs New Haven receive the Bioscience Innovator of the Year award—we feel so incredibly fortunate to call BioLabs our new home! #LifeSciences #NewHaven #GNHCC #Connecticut #Awards #BioCT
-
We are honored to have been recognized by the Greater New Haven Chamber of Commerce and Yale New Haven Health as the Bioscience Company of the Year! Our Chairperson, CEO, and President, John Houston, was present to accept this esteemed award on behalf of #TeamArvinas. This recognition is a testament to the hard work and dedication of our entire team. Thank you for acknowledging our efforts and commitment to innovation and excellence in the field of targeted protein degradation. #Recognition #Awards
-
Last month #TeamArvinas gathered for our annual summer picnic to celebrate our accomplishments and pioneering spirit. We are thankful for our team of innovative and hard-working colleagues, and for the chance to bring everyone together. We may be biased, but we think our employees are nothing short of amazing! We’d also like to extend a special shoutout to our interns on #NationalInternDay. We appreciate the important contributions you have made to our work. Thanks for all you do! #CompanyCulture #TeamBuilding
-
#TeamArvinas is honored to be awarded Bioscience Company of the Year at the 22nd Annual Health Care and Life Science Awards event. Thank you Greater New Haven Chamber of Commerce for this award and your support!
Congratulations to Arvinas who will be honored with the Bioscience Company award at our 22nd Annual Health Care & Life Sciences Awards, presented by Yale New Haven Health Wednesday, July 24th at 3:30pm Canal Dock Boathouse Register now to attend and show your support: https://hubs.li/Q02Gsjl80